- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $867M
- 2 Form D · Jun 2020
- 76 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 3 granted · 37 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised· 1 of 2 same day | Form D · SEC | $821,097,521 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $45,850,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1119 | DURAVAX INC | — | — |
| 1120 | XGENOMES CORP. | — | — |
| 1121 | LYTICON, LLC | — | — |
| 1122 | Sana Biotechnology | — | $867M |
| 1123 | Walden Biosciences | — | — |
| 1124 | Kriya Therapeutics | — | $769M |
| 1125 | VERSATOPE THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Hans BishopDirector
- Douglas ColeDirector
- Nathan HardyExecutive Officer
- Steven HarrDirector · Executive Officer
- Stephen KnightDirector
- James MacDonaldExecutive Officer
- Richard MulliganDirector
- Robert NelsenDirector
- Donald PayanDirector
- Geoffrey von MaltzahnDirector
- Mary Agnes WilderotterDirector
- Patrick YangDirector
Patents
- Engineering Cells With A Transgene In B2M Or Ciita Locus And Associated Compositions And Methodsapplication
- CD8-SPECIFIC Antibody Constructs And Compositions Thereofapplication
- Viral Particles With Fusogen Display And Related Compositions And Methodsapplication
- Methods And Compositions For Modulating Car-t Activitygranted
- CD8-SPECIFIC Antibody Constructs And Compositions Thereofgranted
- Hypoimmunogenic Mait Cells, Methods Of Making And Methods Of Using Sameapplication
- Methods Of Delivery Of Islet Cells And Related Methodsapplication
- Lipid Particles Comprising Variant Paramyxovirus Attachment Glycoproteins And Uses Thereofapplication
- Delivery Of Heterologous Proteinsapplication
- Inducible Systems For Altering Gene Expression In Hypoimmunogenic Cellsapplication
- Methods Of Dosing And Administration Of Engineered Islet Cellsapplication
- Methods Of Transduction Using A Viral Vector And Inhibitors Of Antiviral Restriction Factorsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.